Denosumab is the first gene engineered agent for the treatment of osteoporosis
The incidence of osteoporosis (OP) is growing steadily. Practitioners who long follow up patients with OP frequently ask questions about the duration of treatment with this or that drug particularly in cases of severe OP and at high risk for new fractures when these agents have been used for years a...
Saved in:
| Main Authors: | O A Nikitinskaya, Nataliya Vladimirovna Toroptsova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/436 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01) -
A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
by: Yasumori Sobue, et al.
Published: (2025-07-01) -
EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
by: P. S. Dydykina, et al.
Published: (2015-04-01) -
Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
by: N. Yu. Velts, et al.
Published: (2024-07-01) -
Diagnosis of skeletal fragility due to Loeys-Dietz syndrome and treatment with romosozumab followed by denosumab
by: Yasutaka Tsujimoto, et al.
Published: (2025-06-01)